

Annexure 2

Disclosure regarding Employees Stock Option Scheme (ESOS) pursuant to Rule 12(9) of Companies (Share Capital and Debentures) Rules, 2014 and Regulation 14 of SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.

1) Details related to the Scheme:

As on 31st March 2023, the Company has in place the Newgen Employees Stock Option Scheme – 2014 (“Newgen ESOP Scheme 2014”). This scheme is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (“Regulations”) and Companies Act 2013. All the relevant details as prescribed under above Rule and Regulations are provided below and the same is also available on the website of the Company at <https://newgensoft.com/company/investor-relations/#corporate-governance>.

A. Relevant disclosures in terms of the ‘Guidance note on accounting for employee share-based payments’ issued by ICAI or any other relevant accounting standards as prescribed from time to time.

Please refer Note 35– Share Based Payment, of Notes to the Standalone Financial Statements forming part of the Annual Report.

B. Diluted EPS on issue of shares pursuant to the scheme covered under the regulations in accordance with ‘Indian Accounting Standard (Ind AS) - 33 - Earnings Per Share’ or any other relevant accounting standards as prescribed from time to time.

Fully diluted EPS pursuant to issue of Equity Shares on exercise of ESOPs calculated in accordance with Ind AS - 33 ‘Earning Per Share’ (Consolidated)	Basic: 25.32 Diluted: 25.00
--	--------------------------------

C. Other Details relating to Newgen ESOP 2014.

S. No.	Particulars	Fiscal 2023	Fiscal 2022	Fiscal 2021	Fiscal 2020	Fiscal 2019	Fiscal 2018	Fiscal 2017	Fiscal 2016	Fiscal 2015	
i. a)	Date of shareholders’ approval	As on 31 st March 2023, the Company has in place the Newgen Employee Stock Option Scheme – 2014 (“Newgen ESOP Scheme 2014”), as approved by the shareholders on 13 th November 2014, which was further amended and modified on 28 th July 2017 by the shareholders of the Company, to be compliant with the SEBI (Share Based Employee Benefits) Regulations, 2014 during IPO procedure. Post initial public offer of the Company, the shareholders ratified the Newgen ESOP 2014 on 9 th August 2018, as required under SEBI (Share Based Employee Benefits) Regulations, 2014. This Scheme is further amended by the Board of Directors on 25 th October 2021 and by the Shareholders of the Company on 23 rd June 2022, to be compliant with the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.									
b)	Total number of options approved	The maximum number of 37,83,800 shares can be issued under NEWGEN ESOP 2014.									
c)	Vesting requirements	Set forth below is the vesting schedule, subject to there being a gap of at least one year between the date of grant of options and the vesting of such options.									
		Number of options vested					Vesting schedule				
		10% of the options granted					One year from the date of grant				
		20% of the options granted					Two years from the date of grant				
		30% of the options granted					Three years from the date of grant				
		40% of the options granted					Four years from the date of grant				
d)	Exercise price or pricing formula	₹ 63									
e)	Maximum term of options granted	Once the options have vested, such options have to be exercised within a period of five years from the date on which the last of the options vest. Vesting period shall be as stated in above point (c).									
f)	Source of shares (primary, secondary or combination)	Company uses Trust Route for implementing this Scheme. Source of Share to the Trust as on 31 st March 2023 is Primary. For more information, please refer details related to Newgen ESOP Trust as provided in this disclosure.									
g)	Variation in terms of options	NIL									

S. No.	Particulars	Fiscal 2023	Fiscal 2022	Fiscal 2021	Fiscal 2020	Fiscal 2019	Fiscal 2018	Fiscal 2017	Fiscal 2016	Fiscal 2015	
ii.	Method used to account for NEWGEN ESOP 2014 (Intrinsic or fair value)	Fair Value Method using Black-Scholes Model									
iii.	Where the Company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognised if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the Company shall also be disclosed.	During the financial year 2022-23 Company followed fair value accounting of stock options.									

iv. Option movement during the year

Fiscal Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
a) Number of options outstanding at the beginning of the year	6,03,212	9,01,406	8,84,598	15,57,524	22,43,483	30,61,209	33,84,305	36,53,525	-
b) Number of options granted during the year	20,000	NIL	2,33,000	NIL	NIL	5,62,550	NIL	NIL	36,53,525
c) Number of options forfeited / lapsed during the year	58,625	64,008	NIL	40,723	1,12,466	1,26,096	1,66,525	2,13,175	NIL
d) Number of options vested during the year	29,600	1,68,777	1,34,171	90,605	12,68,724	9,43,211	7,77,170	2,88,188	NIL
e) Number of options exercised during the year	1,15,485	2,34,186	1,98,689	6,49,706	5,73,493	12,54,180	1,56,571	56,045	NIL
f) Number of shares arising as a result of exercise of options	1,15,485	2,34,186	2,16,192	6,32,203	5,73,493	12,54,180	1,56,571	56,045	NIL
g) Money realized by exercise of options (INR), if scheme is implemented directly by the company	72,75,555	1,47,53,718	1,25,17,407	40,93,1478	3,61,30,059	7,90,13,340	98,63,973	35,30,835	NIL
h) Loan repaid by the Trust during the year from exercise price received	Nil	1,52,82,434.99	NIL	2,04,75,000	1,48,05,000	8,53,02,000	1,82,10,000	19,50,000	NIL
i) Number of options outstanding at the end of the year	4,49,102	6,03,212	9,01,406	8,84,598	15,57,524	22,43,483	30,61,209	33,84,305	36,53,525
j) Number of options exercisable at the end of the year	3,28,102	4,20,012	4,89,498	5,71,519	11,22,797	4,45,616	7,77,170	2,88,188	36,53,525

- v. Weighted-average exercise prices and weighted-average fair values of options are disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock.
- Weighted-average exercise prices: ₹ 63/-
 - Weighted-average fair values of options granted during the year: NA

vi. Employee wise details of the options granted:

a. Option granted to Senior Managerial Personnel & KMPs during the year	Nil		
b. Any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year	Name	Designation	No. of ESOPs during the year
	Chetan Goyal	Solutions Architect	5,000
	Mukesh Kumar Gupta	General Manager	5,000
	Kamal Chanana	Project Manager	5,000
	Deepak Kumar Bachani	Senior General Manager	5,000
c. Identified employees who were granted option during any one year equal to or exceeding 1% of the issued capital of the Company (excluding outstanding warrants and conversions) at the time of grant.	Nil		

* The exercise price at which options were granted was ₹ 63/-

vii. A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information:

Particulars	Newgen ESOP 2014 Grant - VI
Date of grant	17-Jan -2023
Fair value of options at grant date	341.99
Share price at grant date	404.60
Exercise price	63
Expected volatility (weighted-average)	43.14%
Expected life (weighted-average)	6 years
Expected dividends	0.95%
Risk-free interest rate (based on government bonds)	7.20%-7.26%

How expected volatility was determined, Historical volatility for the entire period has been taken since the including an explanation of the extent to which expected volatility was based on historical volatility shares are listed in the stock exchange.

The method used and the assumptions made to incorporate the effects of expected early exercise The fair value of the employee share options has been measured using the Black-Scholes formula which presumes the option will be exercised at the end of the term.

Whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition Yes. That has already taken effect through volatility and risk-free rate.

2) Details Related to Trust:

Newgen ESOP 2014 will continue to be implemented through the Trust Route and accordingly, Newgen ESOP Trust was constituted for Newgen ESOP 2014. In Trust Route, the Trust will utilize the shares already held by it and will acquire the shares of the company either through fresh allotment from the company or by way of secondary acquisition, if any.

(i) Details:

S. No.	Particulars	Newgen ESOP Trust (For Newgen ESOP 2014)
1.	Name of the Trust	Newgen ESOP Trust
2.	Details of the Trustee (s)	Mr. Amarendra Kishore Sharan and Mr. Arvind Kaul
3.	Amount of loan disbursed by the company/ any company in the group during the year	NIL
4.	Amount of loan outstanding (repayable to company/ any company in the group) as at the end of the year	NIL
5.	Amount of loan, if any, taken from any other source for which the company or any company in the group has provided any security or guarantee	NIL
6.	Any other contribution made to the Trust during the year	NIL

(ii) Brief details of transactions in shares by the Trust:

S. No.	Particulars	Newgen ESOP Trust (For Newgen ESOP 2014)
1.	Number of shares held at the beginning of the year	6,49,696
2.	Number of shares acquired during the year through (i) primary issuance (ii) secondary acquisition, also as a percentage of paid-up equity capital as at the end of the previous financial year, along with information on weighted average cost of acquisition per share	NIL
3.	Number of shares transferred to the employees / sold along with the purpose thereof	2,34,186
4.	Number of shares held at the end of the year.	4,15,510

(iii) In case of secondary acquisition of shares by the Trust:

Number of shares	As a percentage of paid-up equity capital as at the end of the year immediately preceding the year in which shareholders' approval was obtained Newgen ESOP Trust
Held at the beginning of the year	NIL
Acquired during the year	NIL
Sold during the year	NIL
Transferred to the employees during the year	NIL
Held at the end of the year	NIL

For and on behalf of Board of Directors

Date: 02.05. 2023
Place: New Delhi

Diwakar Nigam
Chairman & Managing Director
DIN: 00263222

Annexure 2A

Disclosure regarding Employees Stock Option Scheme (ESOS) pursuant to Rule 12(9) of Companies (Share Capital and Debentures) Rules, 2014 and Regulation 14 of SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.

1) Details related to the Scheme:

As on 31st March 2023, the Company has in place the Newgen Software Technologies Limited Employees Stock Option Scheme – 2022 (“**Newgen ESOP Scheme 2022**”). This scheme is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (“Regulations”) and Companies Act 2013. All the relevant details as prescribed under above Rule and Regulations are provided below and the same is also available on the website of the Company at <https://newgensoft.com/company/investor-relations/#corporate-governance>.

A. Relevant disclosures in terms of the ‘Guidance note on accounting for employee share-based payments’ issued by ICAI or any other relevant accounting standards as prescribed from time to time.

Please refer Note 35– Share Based Payment, of Notes to the Standalone Financial Statements forming part of the Annual Report.

B. Diluted EPS on issue of shares pursuant to the scheme covered under the regulations in accordance with ‘Indian Accounting Standard (Ind AS) - 33 - Earnings Per Share’ or any other relevant accounting standards as prescribed from time to time.

Fully diluted EPS pursuant to issue of Equity Shares on exercise of ESOPs calculated in accordance with Ind AS - 33 ‘Earning Per Share’ (Consolidated)	Basic: 25.32 Diluted: 25.00
--	--------------------------------

C. Other Details relating to Newgen ESOP 2022.

S. No.	Particulars	Fiscal 2023	
i.	a) Date of shareholders’ approval	As on 31 st March 2023, the Company has in place the Newgen Software Technologies Limited Employee Stock Option Scheme – 2022 (“Newgen ESOP Scheme 2022”), as approved by the shareholders on 23 rd June 2022	
	b) Total number of options approved	The maximum number of 14,00,000 shares can be issued under NEWGEN ESOP 2022.	
	c) Vesting requirements	Set forth below is the vesting schedule, subject to there being a gap of at least one year between the date of grant of options and the vesting of such options.	
		Number of options vested	Vesting schedule
		10% of the options granted	One year from the date of grant
		20% of the options granted	Two years from the date of grant
		30% of the options granted	Three years from the date of grant
		40% of the options granted	Four years from the date of grant
	d) Exercise price or pricing formula	The Exercise Price of the Shares will be based upon the Market Price, along with a maximum discount of 10%, as approved by the Nomination & Remuneration Committee.	
	e) Maximum term of options granted	Once the options have vested, such options have to be exercised within a period of five years from the date on which the last of the options vest. Vesting period shall be as stated in above point (c).	
	f) Source of shares (primary, secondary or combination)	Company uses Trust Route for implementing this Scheme. Source of Share to the Trust as on 31 st March 2023 is Primary. For more information, please refer details related to Newgen ESOP Trust as provided in this disclosure	
	g) Variation in terms of options	NIL	

S. No.	Particulars	Fiscal 2023
ii.	Method used to account for NEWGEN ESOP 2022(Intrinsic or Fair value)	Fair Value Method using Black-Scholes Model
iii.	Where the Company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognised if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the Company shall also be disclosed.	During the financial year 2022-23 Company followed fair value accounting of stock options.

iv. Option movement during the year

Fiscal Year	2023
a) Number of options outstanding at the beginning of the year	NIL
b) Number of options granted during the year	9,41,800
c) Number of options forfeited / lapsed during the year	24,150
d) Number of options vested during the year	NIL
e) Number of options exercised during the year	NIL
f) Number of shares arising as a result of exercise of options	NIL
g) Money realized by exercise of options (INR), if scheme is implemented directly by the company	NIL
h) Loan repaid by the Trust during the year from exercise price received	NIL
i) Number of options outstanding at the end of the year	9,17,650
j) Number of options exercisable at the end of the year	Nil

- v.** Weighted-average exercise prices and weighted-average fair values of options disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock.
- Weighted-average exercise prices: ₹ 364.20/-
 - Weighted-average fair values of options granted during the year: NA

- vi. **i. Employee wise details of the options granted:**
a. Option granted to Senior Managerial Personnel & KMPs during the year

Name	Designation	Fiscal 2023
Aman Mourya	Company Secretary	2,000
b. Any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year		Not Applicable
c. Identified employees who were granted option during any one year equal to or exceeding 1% of the issued capital of the Company (excluding outstanding warrants and conversions) at the time of grant.		Not Applicable

- vii. **A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information:**

Particulars	ESOP Grant in Financial Year 2022-23
Date of grant	
Fair value of options at grant date	200.65
Share price at grant date	404.60
Exercise price	364.20
Expected volatility (weighted-average)	43.14%
Expected life (weighted-average)	5 years
Expected dividends	0.95%
Risk-free interest rate (based on government bonds)	7.07%-7.26%
How expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility	Historical volatility for the entire period has been taken since the shares are listed in the stock exchange.
The method used and the assumptions made to incorporate the effects of expected early exercise.	The fair value of the employee share options has been measured using the Black-Scholes formula which presumes the option will be exercised at the end of the term.
Whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition	Yes. That has already taken effect through volatility and risk-free rate.

2) Details Related to Trust:

Newgen ESOP 2022 will continue to be implemented through the Trust Route and accordingly, Newgen ESOP Trust was constituted for Newgen ESOP 2022. In Trust Route, the Trust will utilize the shares already held by it and will acquire the shares of the company either through fresh allotment from the company or by way of secondary acquisition, if any.

(i) Details:

S. No.	Particulars	Newgen ESOP Trust (For Newgen ESOP 2022)
1.	Name of the Trust	Newgen ESOP Trust
2.	Details of the Trustee (s)	Mr. Amarendra Kishore Sharan and Mr. Arvind Kaul
3.	Amount of loan disbursed by the company/ any company in the group during the year	NIL
4.	Amount of loan outstanding (repayable to company/ any company in the group) as at the end of the year	NIL
5.	Amount of loan, if any, taken from any other source for which the company or any company in the group has provided any security or guarantee	NIL
6.	Any other contribution made to the Trust during the year	NIL

(ii) Brief details of transactions in shares by the Trust under this specific Scheme:

S. No.	Particulars	Newgen ESOP Trust (For Newgen ESOP 2022)
1.	Number of shares held at the beginning of the year (for this scheme)	NIL
2.	Number of shares acquired during the year through (i) primary issuance (ii) secondary acquisition, also as a percentage of paid-up equity capital as at the end of the previous financial year, along with information on weighted average cost of acquisition per share	NIL
3.	Number of shares transferred to the employees / sold along with the purpose thereof	NIL
4.	Number of shares held at the end of the year.	NIL

(iii) In case of secondary acquisition of shares by the Trust:

Number of shares	As a percentage of paid-up equity capital as at the end of the year immediately preceding the year in which shareholders' approval was obtained
	Newgen ESOP Trust
Held at the beginning of the year	NIL
Acquired during the year	NIL
Sold during the year	NIL
Transferred to the employees during the year	NIL
Held at the end of the year	NIL

For and on behalf of Board of Directors

Date: 02.05. 2023
Place: New Delhi

Diwakar Nigam
Chairman & Managing Director
DIN: 00263222

Annexure 2B

Disclosure regarding Restricted Stock Units (RSU) pursuant to Rule 12(9) of Companies (Share Capital and Debentures) Rules, 2014 and Regulation 14 of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

1) Details related to the Scheme:

As on 31st March 2023, the Company has also in place the Newgen Software Technologies Restricted Stock Units Scheme – 2021 (“Newgen RSU - 2021”). This scheme is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (“Regulations”) and Companies Act 2013. All the relevant details as prescribed under the above Rule and Regulations are provided below and the same is also available on the website of the Company at <https://newgensoft.com/company/investor-relations/#corporate-governance>.

A. Relevant disclosures in terms of the ‘Guidance note on accounting for employee share-based payments’ issued by ICAI or any other relevant accounting standards as prescribed from time to time.

Please refer Note number 35 – Share-Based Payment, of Notes to the Standalone Financial Statements forming part of the Annual Report.

B. Diluted EPS on issue of shares pursuant to the scheme covered under the regulations in accordance with ‘Indian Accounting Standard (Ind AS) - 33 - Earnings Per Share’ or any other relevant accounting standards as prescribed from time to time:

Fully diluted EPS pursuant to issue of Equity Shares on exercise of RSUs calculated in accordance with Ind AS - 33 ‘Earning Per Share’ (Consolidated)	Basic: 25.32 Diluted: 25.00
---	--------------------------------

C. Other Details relating to Newgen RSU - 2021

S. No.	Particulars	Fiscal 2023						
i.	a) Date of shareholders’ approval	As on 31 st March 2023, the Company has in place Newgen Software Technologies Restricted Stock Units Scheme – 2021 (“Newgen RSU - 2021”), as approved by the shareholders on 26 th December 2020, which was further amended on 25 th October 2021 by the Board of Directors of the Company, to be compliant with the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021. This Scheme is further amended on 23 rd June 2022 by the Shareholders of the Company, to be compliant with the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.						
	b) Total number of RSUs approved	The maximum number of 14,00,000 shares can be issued under this Scheme.						
	c) Total number of RSUs granted during the year.	35,000						
	d) Vesting requirements	Set forth below is the vesting schedule, subject to the performance matric and eligibility: <table border="1"> <thead> <tr> <th>Time Period</th> <th>% of RSUs to be vested</th> </tr> </thead> <tbody> <tr> <td>At the end of 3rd year from the grant date</td> <td>50% of the RSUs Granted</td> </tr> <tr> <td>At the end of 5th year from the grant date</td> <td>50% of the RSUs Granted</td> </tr> </tbody> </table> <p>*Vesting schedule is subject to the performance matric as defined in the Scheme.</p>	Time Period	% of RSUs to be vested	At the end of 3 rd year from the grant date	50% of the RSUs Granted	At the end of 5 th year from the grant date	50% of the RSUs Granted
Time Period	% of RSUs to be vested							
At the end of 3 rd year from the grant date	50% of the RSUs Granted							
At the end of 5 th year from the grant date	50% of the RSUs Granted							
	e) Exercise price or pricing formula	₹ 10/- each RSU						

S. No.	Particulars	Fiscal 2023
f)	Maximum term of RSUs granted	Once the RSUs have vested, such RSUs have to be exercised within a period of five years from the date on which the last of the RSUs vest. Vesting period shall be as stated in above point (c).
g)	Source of shares (primary, secondary or combination)	Company uses Trust Route for implementing this Scheme. For more information, please refer details related to Newgen RSU Trust as provided in this disclosure.
h)	Variation in terms of RSUs	NIL
ii.	Method used to account for NEWGEN RSU 2021 (Intrinsic or Fair value)	Fair value method
iii.	Where the Company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognised if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the Company shall also be disclosed	During the financial year 2022-23 Company followed fair value accounting of stock RSUs.

iv. RSUs movement during the year

S. No.	Fiscal Year	2022-23
a	Number of RSUs outstanding at the beginning of the year	13,60,000
b	Number of RSUs granted during the year	35,000
c	Number of RSUs forfeited / lapsed during the year	90,000
d	Number of RSUs vested during the year	NIL
e	Number of RSUs exercised during the year	NIL
f	Number of shares arising as a result of exercise of RSUs	NIL
g	Money realized by exercise of RSUs (INR), if scheme is implemented directly by the Company	NIL
h	Loan repaid by the Trust during the year from exercise price received	NIL
i	Number of RSUs outstanding at the end of the year	13,05,000
j	Number of RSUs exercisable at the end of the year	NIL
v.	Weighted-average exercise prices and weighted-average fair values of RSUs disclosed separately for RSUs whose exercise price either equals or exceeds or is less than the market price of the stock.	Not Applicable

vi. i. Employee wise details of the RSUs granted:

a. RSUs granted to Senior Managerial Personnel & KMPs during the year NIL

b. Any other employee who receives a grant in any one year of RSUs amounting to 5% or more of RSUs granted during that year.

Name	Designation	Fiscal 2023
Mr. Harinder Pal Singh Sethi	Trade finance and LMS Consultant	35,000

c. Identified employees who were granted RSUs during any one year equal to or exceeding 1% of the issued capital of the Company (excluding outstanding warrants and conversions) at the time of grant. NIL

vii. A description of the method and significant assumptions used during the year to estimate the fair value of RSUs including the following information:

Particulars	Newgen RSU – 2021 Grant - III
Date of grant	18-Oct-2022
Fair value of options at grant date	334.03
Share price at grant date	362.05
Exercise price	10
Expected volatility (weighted-average)	38.60
Expected life (weighted-average)	6.5 years
Expected dividends	0.95%
Risk-free interest rate (based on government bonds)	7.28%-7.34%
The method used and the assumptions made to incorporate the effects of expected early exercise	The fair value of the employee share RSUs has been measured using the Black-Scholes formula which presumes the RSUs will be exercised at the end of the term.
How expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility.	The fair value of the employee share options has been measured using the Black-Scholes formula which presumes the RSUs will be exercised at the end of the term.
Whether and how any other features of the RSUs grant were incorporated into the measurement of fair value, such as a market condition	Yes. That has already taken effect through volatility and risk-free rate.

2) Details Related to Trust:

Newgen RSU - 2021 will continue to be implemented through the Trust Route and accordingly Newgen RSU Trust was constituted to implement the Scheme. In Trust Route, the Trust will acquire the shares of the Company either through fresh allotment from the Company or by way of secondary acquisition, if any.

(i) Details:

1. Name of the Trust	Newgen RSU Trust
2. Details of the Trustee (s)	Mr. Arvind Kaul Mr. Rajesh Pathak
3. Amount of loan disbursed by the company/ any company in the group during the year	NIL
4. Amount of loan outstanding (repayable to company/ any company in the group) as at the end of the year	NIL
5. Amount of loan, if any, taken from any other source for which the company or any company in the group has provided any security or guarantee	NIL
6. Any other contribution made to the Trust during the year	NIL

(ii) Brief details of transactions in shares by the Newgen RSU Trust:

1.	Number of shares held at the beginning of the year	NIL
2.	Number of shares acquired during the year through (i) primary issuance (ii) secondary acquisition, also as a percentage of paid-up equity capital as at the end of the previous financial year, along with information on weighted average cost of acquisition per share	NIL
3.	Number of shares transferred to the employees / sold along with the purpose thereof	NIL
4.	Number of shares held at the end of the year.	NIL

(iii) In case of secondary acquisition of shares by the Trust:

Number of shares	As a percentage of paid-up equity capital as at the end of the year immediately preceding the year in which shareholders' approval was obtained
	Newgen RSU Trust
Held at the beginning of the year	NIL
Acquired during the year	NIL
Sold during the year	NIL
Transferred to the employees during the year	NIL
Held at the end of the year	NIL

For and on behalf of Board of Directors

Date: 02.05. 2023
Place: New Delhi

Diwakar Nigam
Chairman & Managing Director
DIN: 00263222